DSIP, or delta sleep-inducing peptide, is a naturally occurring neuropeptide reported to influence sleep and stress responses, though its action in humans stays unclear. Human research remains thin, and it trades as a research chemical, not an FDA-approved drug. Educational only, not medical advice.
Delta sleep-inducing peptide, a naturally occurring neuropeptide reported to influence sleep regulation and stress/neuroendocrine responses; mechanism in humans is not well characterized.
Half-life
Uncertain; reported to be very short (minutes) in circulation.
Regulatory status
Not FDA-approved. The FDA has noted human research on DSIP is still lacking. Was on FDA Category 2; per April 2026 reporting slated for removal from Category 2 (compounding reconsideration only). Research chemical / gray-market.
Safety
Limited human safety data; side effects poorly characterized; long-term safety unknown.
Evidence
Limited human data; mostly older/animal studies and anecdotal use.
Sources
Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man: multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983;9(4):197-206. https://pubmed.ncbi.nlm.nih.gov/6895513/
Koplik EV, Umriukhin PE, Konorova IL, et al. Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection. Neurosci Behav Physiol. 2008;38(9):953-957. https://pubmed.ncbi.nlm.nih.gov/18975112/
Solnyshkova TG, et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021;26(17):5173. https://pubmed.ncbi.nlm.nih.gov/34500610/
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. DSIP may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.